While GLP-1 (glucagonlike peptide 1) agonist drugs such as semaglutide target a single hormone receptor that regulates hunger, GLP-3s target multiple receptors, including GLP-1, the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon receptor
According to the FDA prescribing information for Wegovy, in the STEP clinical trials, cholelithiasis was reported in approximately 1.6% of semaglutide-treated patients compared to 0.7% of placebo recipients
Flag encounters where nerve conduction studies or specialist notes appear in the same date range
Cigrovski BerkovicMStrolloF
All had started treatment with GLP-1 medications, including liraglutide (Victoza), semaglutide (Ozempic), or tirzepatide (Mounjaro), and had at least six months of follow-up data